Podcasts about bite

This hour Henry reacts to Bernie Sanders comments about not wanting to fund the Iran War, an overreaction leads to a lawsuit and a bad look, plus we have Bite of the Night and Headlines

See omnystudio.com/listener for privacy information.

This hour Henry wonders why is there such a divide between out state Minnesota and the metro, he talks Vikings and more NFL with Matthew Coller from Purple Insider, plus we have Bite of the Night and Headlines.

Dr. Monty Pal and Dr. Vamsi Velcheti discuss the evolving treatment landscape in EGFR-mutated non-small cell lung cancer, including landmark trials like FLAURA2, novel drug therapies, and the growing importance of ctDNA and MRD testing. TRANSCRIPT Dr. Monty Pal: Hello, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. Monty Pal. I'm a medical oncologist and professor and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center in Los Angeles. Today, I'm truly delighted to introduce Dr. Vamsi Velcheti, who's a professor of medicine and the chief of hematology-oncology at the Mayo Clinic in Jacksonville, Florida. We'll be discussing the expanding treatment landscape in EGFR-positive lung cancer and how to navigate the challenges of balancing treatment efficacy, toxicity, and patient quality of life in the EGFR-positive space.  Just FYI, our full disclosures are available in the transcript of this episode.  Vamsi, it's so great to have you on the podcast. Thank you so much for being here. Dr. Vamsi Velcheti: Thank you, Monty. It's a pleasure to be here with you. It's a really exciting topic and there are a lot of updates in the EGFR space. Dr. Monty Pal: So, I'm going to need your help with this because I'll be honest with you, I see very little lung cancer, if any, in my practice. I'm pretty much exclusively kidney cancer these days. I'm coming on 20 years at City of Hope now, and I still remember when trials like ECOG 1599 were presented with, you know, platinum doublets. And, of course, the field has changed a lot since then. But tell us a little bit about the first-line landscape, and I think just for the sake of time, we're going to stick with EGFR-positive disease here. What does it look like these days? Dr. Vamsi Velcheti: Monty, the foundation of care remains the third-generation EGFR inhibitors. These are selective EGFR inhibitors, like osimertinib. We've had an evolution of the development of these TKIs. Like, you know, we had the first-generation, second-generation, not-so-selective EGFR inhibitors. Now we have mutant-selective EGFR inhibitors in the clinic, and they're doing a really good job. And these are quite effective in patients who have classical activating mutations. But the reality is that these have not been transformative. These agents have fundamentally changed the response patterns, excellent CNS penetration, and very good tolerability profile. However, we don't see a lot of durability in terms of the response. So, what's different today is now there have been several trials in combination with these third-generation EGFR inhibitors that have really laid the foundation of how we kind of think about EGFR-positive disease. At the high level, there are a lot of challenges to selecting the patients for these combination-based modalities. I'm assuming we'll be talking more about these different trials and different approaches. Some of these combination-based strategies have really moved the needle in terms of improving overall survival and really improving long-term outcomes and durability in our patients. Dr. Monty Pal: And we are going to get into the weeds on this in just a moment. But I did kick off this podcast talking about chemotherapy, ECOG 1599. It does seem as though chemotherapy is still a component of management in advanced non-small cell lung cancer. So, can you tell us about, perhaps first, you mentioned osimertinib, you know, some of these next-generation EGFR inhibitors. Tell us about the role of chemo plus osimertinib. Dr. Vamsi Velcheti: That's exactly where I was going with the combination-based strategies. You know, we first started off with our earlier trials in the EGFR space evaluating the question of, are targeted therapies, are these highly effective, third-generation, EGFR-selective inhibitors, superior to platinum-doublet chemotherapy? And we've had multiple trials demonstrating that, like the FLAURA trial and in the past with second-generation EGFR inhibitors like erlotinib and gefitinib and afatinib. So, we know that these TKIs actually perform better than platinum-doublet chemotherapy. Now, we have a large, global, phase 3 trial data from the FLAURA2 trial, which looks at the question, "Hey, you know, osimertinib is better than chemotherapy, platinum-doublet chemotherapy. Can we do even better by combining osimertinib with platinum-doublet chemotherapy?" So, FLAURA2 answered that question. This is a large, phase 3 trial, and it's a positive trial with improved durability of disease control and improving overall survival with combination with chemotherapy. So, it's a very important and landmark trial, and essentially combining osimertinib with a platinum-based chemotherapy improved responses, deepened responses, and improved overall survival and really changing the disease trajectory. And this strategy is definitely compelling, especially in patients who have certain clinical high-risk features like, you know, patients who have high disease burden or patients who are sometimes having rapid disease progression early on osimertinib, especially with patients who have a lot of visceral disease burden. So, intensifying treatments up front could alter the natural trajectory of the disease. Dr. Monty Pal: So, you sort of alluded to this in that last part there, but is that kind of how you in clinical practice select? Is it based on, you know, visceral involvement? Is it based on rapidity of disease where you think about adding chemotherapy to osimertinib? Maybe you can give us the corollary. Which patients do you just use osimertinib alone in, for instance? Dr. Vamsi Velcheti: Definitely, there are some patients who have low disease burden and they have the classical mutations, like an exon 19 deletion. And these patients, especially if they don't have a lot of disease burden, they don't have CNS involvement, there may be a subset of patients who could just do fine on osimertinib of course, with close monitoring of the disease. I guess we'll get into that later, how do we do that with either ctDNA or like closer imaging or both. So, there may be some opportunity to kind of escalate patients' treatments based on certain clinical characteristics or radiographic characteristics or certain biological characteristics informed by ctDNA or other approaches. Dr. Monty Pal: No, that's interesting. And you're right, we will chat about ctDNA in just a bit. But before we get there, I think one of the big agents that has really sort of come to the fore in advanced non-small cell lung cancer is amivantamab. I've heard a lot about this in the context of even kidney cancer because in certain subsets, I'm interested in MET-directed therapies and so forth, right? So maybe tell us a little bit about the mechanism of amivantamab first, and then maybe tell us about this pivotal MARIPOSA trial where it's combined with lazertinib. Dr. Vamsi Velcheti: So, the MARIPOSA trial compared lazertinib alone with amivantamab plus lazertinib. And this trial demonstrated overall survival advantage, and there were key differences in terms of tolerability and the safety of amivantamab, which is an EGFR and MET bispecific, and there were certain kind of unique toxicity profiles that make it a little different than the intensification approach with chemotherapy through the FLAURA2 trial. So, there's a trade-off in terms of the toxicity profile. It's a different agent and a different management protocol in terms of dermatological toxicity management that clinicians need to be comfortable with. And also, there are certain unique issues in terms of amivantamab; there's a higher rate of infusion-related reactions, there's an increased risk for edema and VTEs because of amivantamab. Certainly a different toxicity profile, different management paradigm there in terms of longitudinal care of these patients requiring dermatological care and like, you know, close monitoring and prophylaxis VTEs. But having said that, definitely it's a different strategy, and it kind of changes the biology and the natural history of the cancers, and we do see some durability of responses that we see with the MARIPOSA. So, it's certainly a great alternative, at least for some patients. Dr. Monty Pal: That was a great overview of MARIPOSA. Now comes the really difficult question, which is, how do you choose between the two? You have these two great options, right, for EGFR-positive patients. You've already highlighted some of the distinctions in terms of toxicity. I think the audience is well aware of the side effects of chemo-doublet, perhaps even the EGFR-based therapies. Amivantamab is quite new. Give us a sense of how you in clinical practice decide between the two potential options here. Dr. Vamsi Velcheti: Yeah, I think that's the big challenge. I think these are two independent strategies that have evolved through the phase 3, and both of them have demonstrated overall survival benefit. So, the way I think about this is in three dimensions, right? Like, the disease biology, the patient priorities, and feasibility of care delivery. So, when I talk about the disease biology, you know, the mechanism is very different, and MET is a very dominant driver of disease in EGFR-altered patients and it's a significant mechanism of resistance, acquired resistance to TKIs. So, certainly I think there's a patient population that could benefit from a MET-directed therapy up front. However, we don't have great data to kind of really demonstrate how using amivantamab in the front line is going to change that. And are there like perhaps like some patients who we could identify who would benefit from such a strategy? Very recently, there have been some approvals in the second-line setting in lung cancer, not in the EGFR space, but like in generally in lung cancer, with the MET ADCs, and those drugs are approved with a companion diagnostic, which requires MET IHC testing. So, what has happened, at least in large academic practices and also I think in the community now, they have been checking for MET IHC expression more routinely in lung cancer. What we have been doing in our institution is we have been doing MET IHC as a reflex for all patients with EGFR, not just EGFR, but all non-small cell lung cancer patients. What that has done is now, like, we have been increasingly testing patients with EGFR for MET. And there's clearly a subset of patients who have de novo MET expression and a high MET expression. And those patients, I've been kind of like preferentially treating them with the MARIPOSA regimen. But again, I have to caution the audience that we still don't have data that MET IHC is going to help us make those decisions, whether it's better than like a FLAURA2 regimen. But however, in the second-line setting in the CHRYSALIS trial, we know that MET is a very powerful predictor of response to amivantamab. We really need more data there, but that's what I have been doing in my practice. But also, there's a lot of patient preference here. Like, there are some patients who don't want chemotherapy, and they want a non-chemotherapy approach. So, certainly there are some patients who prefer to have amivantamab. And now with the amivantamab, the subcutaneous version, the infusion reactions and the logistics of actual administration of amivantamab are more favorable with the subcutaneous approval. So, those are some of the elements that we need to take into account. Dr. Monty Pal: Well, I want to hone in on that because this subcutaneous administration route has been a big debate that I've seen on social media. Tell us, how much easier does it actually make the amivantamab experience? Does it cut down on the rash? Is it just infusion reactions? What's been your clinical experience? Vamsi Velcheti, MD: So, the subcutaneous administration of amivantamab has definitely improved the infusion reaction issue. Very rarely patients have infusion reaction now with the subcutaneous injections. And also, the infusion time is much, much shorter. Like we don't need a lot of infusion time, which is sometimes a challenge in busy infusion clinics. We need to take that into account. As far as the impact of the subcutaneous formulation on dermatological toxicity, we haven't really seen significant difference in terms of the intensity or rates of dermatological toxicity with subcutaneous. The benefits are really with the infusion reaction, the ease of administration. And interestingly, in the PALOMA trial, it also seems to be, even though this was not the primary endpoint of the study, there seems to be some suggestion that the subcutaneous amivantamab seems to have improved OS compared to the IV amivantamab. We don't really understand why, but that's a finding from the trial that's very intriguing. Dr. Monty Pal: That is really fascinating. I'm kind of curious to see how that's going to pan out. I'm going to shift gears a little bit here. And, you know, as we sort of close, I wanted to talk a little bit about biomarkers. I mean, this is obviously not a lung cancer-specific issue. It's something we think about across the board. But what I will say is that there are certain commonalities, and in bladder cancer, we think a lot now about ctDNA. But you've been way ahead of the game in lung cancer. Tell us how you guys use ctDNA, maybe both from the standpoint of monitoring for mutational status, but if you can, maybe offer some insights into some of these new MRD tests that are available too. Dr. Vamsi Velcheti: Yeah, it's rapidly evolving. Certainly, I think in the lung cancer space, you know, this has really kicked off in the lung cancer space with incorporating ctDNA into the workflow. Of course, you know, like baseline evaluation, we still kind of heavily rely on tissue genomic sequencing. But as you know, with targeted therapy, a lot of these patients have disease that evolves over time, and changes in terms of mutational pattern driving acquired resistance is a major issue across different molecular subtypes. And especially so in EGFR, when there are certain actionable opportunities associated with that transformation. So, we need to kind of have like a longitudinal snapshot of how we monitor these patients. So, the ctDNA has come to be like a tool that has now come to the forefront of clinical workflow, and almost all my patients who are having disease progression have ctDNA for kind of evaluating for resistance and informing treatment decisions, especially in EGFR. But having said that, there are a lot of challenges in terms of using ctDNA as a tool for monitoring. There are a lot of different types of assays and different platforms, and being able to use this as a quantitative tool that would be used along with the CT scans that we routinely use in clinical practice has been a challenge. And I think I would love to hear your perspectives as well, Monty, about how you're thinking about that in bladder and other disease contexts. But having said that, I think there's a lot of opportunity to incorporate ctDNA and MRD assays into clinical decision-making. Right now, in terms of clinical trials and clinical development, there have been some very interesting trials that are currently ongoing, especially in the EGFR space. We know that patients who clear ctDNA, based on some retrospective data and also like some retrospective-prospective data from trials that have already read out, that patients who clear ctDNA early with target therapy tend to do much better. They have a longer durability of response. There may be a subset of patients who have, even though they're having radiographic response, they have persistent ctDNA after a certain time point of initiation of targeted therapy. Those patients may require escalation of therapy. We don't yet know. I can't recommend that as a standard right now because we don't have clinical evidence to support that. But however, some of the clinical trials, like the ELIOS trial that's being done right now, that's actually completed enrollment, we'll hopefully see the results very soon. So, there is an emerging thought that instead of intensifying treatment for all patients with EGFR, there may be a population that may be just fine with frontline osimertinib monotherapy and introducing the intensification strategy at the time of emergence of MRD or progression on ctDNA before radiographic progression. So, there are a lot of adaptive molecular response criteria that we are kind of exploring in clinical trials that could inform how the future is going to look like for EGFR and other perhaps targeted therapies as well. So, it's fascinating, and I think there's a lot of opportunity there. Dr. Monty Pal: You know, you asked for my perspective. I actually think that what you highlighted there is the most interesting opportunity for ctDNA: the ability to de-escalate therapy. In terms of drug development, we've done so much to bring new therapies to patients, and now it's a bit of an embarrassment of riches, but the downside is that I feel like we tend to overtreat a lot of patients in the clinic. So, I definitely view MRD, you know, some of these other ctDNA techniques with methylation and so forth that may not be sort of tumor-dependent or bespoke could be incredibly, incredibly helpful. You touched on sort of the future, right, in this last section here with biomarkers. But give us a sense now in terms of novel drug therapies in the EGFR space. What are you most excited about moving forward in 2026 and beyond? Dr. Vamsi Velcheti: Yeah, I think there's a lot going on in this space, and not just this space, but across lung cancer and others as well. Like looking at the next generation of targets for ADCs. And I think a lot of these have to do with…so far in the drug development space, as you know, the improvements in clinical outcomes has been very incremental. So, we really need to make that big leap. And I think the big leap is not going to come from, in my opinion, from the next ADC, but it's going to come from how we tailor treatments and how we monitor disease better and how do we kind of incorporate the next treatment earlier and not wait for the radiographic progression. So, there's a lot of opportunity there to integrate biomarkers and dynamic biomarkers into clinical trial design and incorporating the recent advances in terms of drug design. You know, we have a lot of assets in the EGFR space, the next-generation EGFR inhibitors that are kind of designed with resistance in mind and rational combination, knowing when to introduce those combinations is also equally important. So, there's a lot going on, really exciting times to be in drug development. The one thing that I really hope will come to the forefront in drug development, not just for lung cancer, but all disease groups, is to kind of really be thoughtful about how we incorporate these really cool molecular monitoring tools and creating a composite score with imaging to be able to like really design the next generation of clinical trials. Dr. Monty Pal: You're so spot-on with that. I definitely think that we're getting to this point where, you know, we could think about the next BiTE, the next CAR-T, the next ADC. But, you know, maybe it's time for us to start really honing in on appropriate applications of these drugs, honing in on the right dose and what have you, because I definitely see some issues there.  Vamsi, this has just been terrific. I really want to thank you so much for sharing your fantastic insights with us today on the ASCO Daily News Podcast, and I really appreciate all your efforts to move the field of lung cancer forward. Dr. Vamsi Velcheti: Thanks, Monty. I really enjoyed the conversation. Dr. Monty Pal: Yeah, this was terrific.  And thanks to our listeners as well. If you value the insights that you hear from the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:     Dr. Monty Pal   @montypal  Dr. Vamsi Velcheti @VamsiVelcheti Follow ASCO on social media:          ASCO on X    ASCO on Bluesky         ASCO on Facebook          ASCO on LinkedIn          Disclosures:       Dr. Monty Pal:      Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview     Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical     Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis   Dr. Vamsi Velcheti:   Honoraria: Galvanize Therapeutics  Consulting or Advisory Role: Bristol-Myers Squibb, Merck, AstraZeneca/MedImmune, GSK, Amgen, Taiho Oncology, Novocure, Regeneron, Takeda, Janssen Oncology, Picture Health Research Funding (Inst.): Genentech, Trovagene, Eisai, OncoPlex Diagnostics, Alkermes, NantOmics, Genoptix, Altor BioScience, Merck, Bristol-Myers Squibb, Atreca, Heat Biologics, Leap Therapeutics, RSIP Vision, GlaxoSmithKline

This hour Henry reacts to the United States loss at the World Baseball Classic and players removing their medals, he talks with Fox 9 News Anchor Kelcey Carlson, plus we have Bite of the Night and Headlines.

The hits just keep on rolling as a handful of Iranian leaders are eliminated over the past 24 hours, reminding Howie of a Queen song. Plus, Karen Spilka compares ICE to what the Nazis did in the '30s and '40s, and Maura Healey again claims it's her job to make people feel safe. If that's her job Howie thinks she's doing terribly at it.  Visit the Howie Carr Radio Network website to access columns, podcasts, and other exclusive content.

Join Host Bree Carlile as she reads White Fang by Jack London.Follow along as Bree shares her passion for books, audiobooks, and bringing stories to life in these classic novel audiobooks. Busy schedule? Each episode is just one chapter, or bite of a classic novel, play or short story, which means you can fit in your reading goals while getting ready for work, bed, or on your commute.Follow, rate, and review Bite at a Time Books where we read you your favorite classics, one bite at a time. Available wherever you listen to podcasts.Check out our website, or join our Facebook Group!Get exclusive Behind the Scenes content on our YouTube!We are now part of the Bite at a Time Books Productions network!If you ever wondered what inspired your favorite classic novelist to write their stories, what was happening in their lives or the world at the time, check out Bite at a Time Books Behind the Story wherever you listen to podcasts.Follow us on all the socials: Instagram - Twitter - Facebook - TikTokFollow Bree at: Instagram - Twitter - Facebook

This hour Henry wonders who you like in the NCAA tournament, he talks about the NCAA Women's Basketball tournament with Sloane Martin, plus we have Bite of the Night and Headlines.

Ben Maller talks about Vikings coach Kevin O'Connell praising Kyler Murray and indicating that he is a long-term option for the team, Bill Belichick's girlfriend Jordon Hudson calling herself a "gold digger", Cite the Bite, and much more!See omnystudio.com/listener for privacy information.

Join Host Bree Carlile as she reads White Fang by Jack London.Follow along as Bree shares her passion for books, audiobooks, and bringing stories to life in these classic novel audiobooks. Busy schedule? Each episode is just one chapter, or bite of a classic novel, play or short story, which means you can fit in your reading goals while getting ready for work, bed, or on your commute.Follow, rate, and review Bite at a Time Books where we read you your favorite classics, one bite at a time. Available wherever you listen to podcasts.Check out our website, or join our Facebook Group!Get exclusive Behind the Scenes content on our YouTube!We are now part of the Bite at a Time Books Productions network!If you ever wondered what inspired your favorite classic novelist to write their stories, what was happening in their lives or the world at the time, check out Bite at a Time Books Behind the Story wherever you listen to podcasts.Follow us on all the socials: Instagram - Twitter - Facebook - TikTokFollow Bree at: Instagram - Twitter - Facebook

This hour Steve Thomson (in for Henry Lake) gets into the big differences in NIL money when it comes to the Men's Basketball Tournament, shooting free throws is a lost art, plus we have Bite of the Night and Headlines.

Nvidia’s growth is tied to a massive global build-out of AI infrastructure — but most of the spending isn’t coming from consumers. It’s coming from hyperscalers like Amazon, Microsoft, Meta and Google pouring hundreds of billions into data centres and AI chips. We unpack whether that spending boom can continue, why Big Tech is now turning to debt markets to fund it, and what happens if expectations around AI start to cool. This bite is from our episode ‘The winners and losers of an AI revolution’. For more or to watch on YouTube—check out http://linktr.ee/sharedlunch Shared Lunch is brought to you by Sharesies Australia Limited (ABN 94 648 811 830; AFSL 529893) in Australia and Sharesies Limited (NZ) in New Zealand. It is not financial advice. Information provided is general only and current at the time it’s provided, and does not take into account your objectives, financial situation and needs. We do not provide recommendations and you should always read the disclosure documents available from the product issuer before making a financial decision. Our disclosure documents and terms and conditions—including a Target Market Determination and IDPS Guide for Sharesies Australian customers—can be found on our relevant Australian or NZ website. Investing involves risk. You might lose the money you start with. If you require financial advice, you should consider speaking with a qualified financial advisor. Past performance is not a guarantee of future performance. Appearance on Shared Lunch is not an endorsement by Sharesies of the views of the presenters, guests, or the entities they represent. Their views are their own.See omnystudio.com/listener for privacy information.

Ryan Spahn is a Drama Desk Award–winning actor and writer. Select Off-Broadway: Richard II (Red Bull), Danger and Opportunity (East Village Basement), The Antiquities (Playwrights Horizons), Jordans (The Public), Merry Me (NYTW), Good Enemy (Audible), Jane Anger (New Ohio), Summer & Smoke (CSC), Daniel's Husband (Westside), Moscow x6 (MCC), Exit Strategy (Primary Stages), Gloria (Vineyard). Select TV/Film: Sub/liminal, Zero Day, Elsbeth, AHS: Delicate, Succession, Modern Love, The Bite, Chicago P.D. Ryan co-wrote the feature film He's Way More Famous Than You and wrote the play Inspired By True Events (Concord Theatricals, Theatrely's “Best of 2024.”). Juilliard graduate and the first teenaged Borg on Star Trek: Voyager. Learn more about your ad choices. Visit podcastchoices.com/adchoices

You might have received a Social Security cost-of-living increase this year — but did your net check actually go up?  A recent Wall Street Journal article highlights how rising Medicare premiums and IRMAA surcharges are offsetting those increases for millions of retirees - and "takes a bigger bite out of Social Security checks". Then, a listener writes in "How to convince my husband's parents to spend their money. We don't need it." Tune in to hear that one! And we wrap it up with our "Retire to Something" segment from Dave in Massachusetts.  Resource: Wall Street Journal article by Laura Sanders: The Medicare Charge That's Taking a Bigger Bite Out of Social Security Checks   Connect with Benjamin Brandt: Subscribe to the This Week in Retirement: http://thisweekinretirement.com Get the Retire-Ready Toolkit: http://retirementstartstodayradio.com Work with Benjamin: https://retirementstartstoday.com/start Get the book!Retirement Starts Today: Your Non-financial Guide to an Even Better Retirement Follow Retirement Starts Today in:Apple Podcasts, Spotify, Overcast, Pocket Casts, Amazon Music, or iHeart  

Jane Wesman, founder of Jane Wesman Public Relations, Inc., is one of the country's top experts in book publicity and marketing with an impressive track record of creating national bestsellers, particularly in the areas of business, leadership, and personal growth. The author of Dive Right In - The Sharks Won't Bite, Jane is also a mentor and advisor to entrepreneurs and startups. A strong believer in giving back, Jane currently serves as co-president of the nonprofit organization Women's Media Group.In today's episode of Smashing the Plateau, you will learn how to build an authentic marketing foundation that attracts clients without draining your energy.Jane and I discuss:Jane's involvement with NAWBO and Women's Media Group [03:02]Why marketing feels like an energy leak for many entrepreneurs [03:41]The importance of building an authentic website as your foundation [05:25]Why you can't do everything in marketing and must choose strategically [06:06]The problem with trying to be something for everyone [07:01]Why LinkedIn and newsletters are essential for consultants [08:08]How to integrate your website, LinkedIn, and newsletter [08:39]Why you need to go narrow and go deep with your expertise [09:41]How Jane stayed focused on book marketing and said no to other opportunities [11:17]Using outside services and building a team for marketing [13:06]Other marketing channels: speaking, podcasts, and guest articles [14:58]The importance of consistency in marketing [15:36]Why everyone needs a team, even solopreneurs [16:23]The value of being involved in nonprofit organizations [20:09]Leadership lessons Jane learned from volunteer work [21:00]Why being a member isn't enough—you need to join committees or boards [23:31]Jane's key message: start with your website and be consistent [25:23]______________________________________________________________About Smashing the PlateauSmashing the Plateau shares stories and strategies from corporate refugees: mid-career professionals who've left corporate life to build something of their own.Each episode features a candid conversation with someone who has walked this path or supports those who do. Guests offer real strategies to help you build a sustainable, fulfilling business on your terms, with practical insights on positioning, growth, marketing, decision-making, and mindset.Woven throughout are powerful reminders of how community can accelerate your success.______________________________________________________________Take the Next Step• Experience the power of community.Join a live guest session and connect with peers who understand the journey:https://smashingtheplateau.com/guest• Not ready to join live yet? Stay connected.Get practical strategies, stories, and invitations delivered to your inbox:https://smashingtheplateau.com/news

Join Host Bree Carlile as she reads White Fang by Jack London.Follow along as Bree shares her passion for books, audiobooks, and bringing stories to life in these classic novel audiobooks. Busy schedule? Each episode is just one chapter, or bite of a classic novel, play or short story, which means you can fit in your reading goals while getting ready for work, bed, or on your commute.Follow, rate, and review Bite at a Time Books where we read you your favorite classics, one bite at a time. Available wherever you listen to podcasts.Check out our website, or join our Facebook Group!Get exclusive Behind the Scenes content on our YouTube!We are now part of the Bite at a Time Books Productions network!If you ever wondered what inspired your favorite classic novelist to write their stories, what was happening in their lives or the world at the time, check out Bite at a Time Books Behind the Story wherever you listen to podcasts.Follow us on all the socials: Instagram - Twitter - Facebook - TikTokFollow Bree at: Instagram - Twitter - Facebook

Bonus [Art] Blankman (1994) Coming up next...: Homework [MCP] Captive State (2019) Homework [Fonso] Project Hail Mary (2026)

In this 512th episode of ”Elton Jim” Turano's “CAPTAIN POD-TASTIC,” Jim Turano takes a bite out of the latest viral trend — eating a hamburger!

Chaz and AJ asked Vince to go into New Haven yesterday and talk to the fun people at the St. Patrick's Day parade. Vince met Quentin from Ireland, who showed no hesitation breaking into song. Plus, Big Mike was at the Loud Island Bite Bash last week, and spoke to concert goers about their craziest concert experiences. (0:00) Jason Page was on the phone with Chaz and AJ this morning to talk sports, starting with yet another UConn loss at the hands of St. John's. Plus, some talk about the United States team in the World Baseball Classic, and Jason might have already broken his promise regarding the Giants. (15:29) Mike and Mike were in studio with Chaz and AJ this morning to recap all of the Oscars. Did the right movies win? Was Conan a good host? Has Barbra Streisand stopped talking yet? (27:07)

Last year, Elon Musk's Department of Government Efficiency took a chainsaw to the federal government, slashing jobs and cutting programs in the name of eliminating waste, fraud, and abuse. While it did not reduce spending, current and former government officials tell CNN that some of the cuts are hampering government readiness amid the Iran war. Now, the government is looking to ramp up hiring again – but only with workers who align with the Trump administration's priorities. We hear from a former federal worker about how last year's cuts impacted her, and from an expert who says he's concerned about adding more political appointees to the mix.  For more: ‘A shell of our former self': How Trump and Musk's spending cuts are hampering US government readiness amid the Iran war  ---  Guests: Melissa Patsalides & Max Stier, Partnership for Public Service President and CEO  Host: David Rind  Producer: Paola Ortiz  Showrunner: Felicia Patinkin  Editorial Support: Tami Luhby Photo: Allison Robbert/AFP/Getty Images Learn more about your ad choices. Visit podcastchoices.com/adchoices

Today we give you our discussion with Dr. Yana Suchy about her role as Editor-in-Chief for the journal, The Clinical Neuropsychologist, or TCN. Show notes are available at www.NavNeuro.com/187 _________________ If you'd like to support the show, here are a few easy ways: 1) Get CE credits for listening to select episodes: www.NavNeuro.com/INS  2) Tell your friends and colleagues about it 3) Subscribe (free) and leave an Apple Podcasts rating/review: www.NavNeuro.com/itunes 4) Check out our book Becoming a Neuropsychologist, and leave it an Amazon rating   Thanks for listening, and join us next time as we continue to navigate the brain and behavior! [Note: This podcast and all linked content is intended for general educational purposes only and does not constitute the practice of psychology or any other professional healthcare advice and services. No professional relationship is formed between hosts and listeners. All content is to be used at listeners' own risk. Users should always seek appropriate medical and psychological care from their licensed healthcare provider.]

Join Host Bree Carlile as she reads White Fang by Jack London.Follow along as Bree shares her passion for books, audiobooks, and bringing stories to life in these classic novel audiobooks. Busy schedule? Each episode is just one chapter, or bite of a classic novel, play or short story, which means you can fit in your reading goals while getting ready for work, bed, or on your commute.Follow, rate, and review Bite at a Time Books where we read you your favorite classics, one bite at a time. Available wherever you listen to podcasts.Check out our website, or join our Facebook Group!Get exclusive Behind the Scenes content on our YouTube!We are now part of the Bite at a Time Books Productions network!If you ever wondered what inspired your favorite classic novelist to write their stories, what was happening in their lives or the world at the time, check out Bite at a Time Books Behind the Story wherever you listen to podcasts.Follow us on all the socials: Instagram - Twitter - Facebook - TikTokFollow Bree at: Instagram - Twitter - Facebook

Genesis 3:1-21. The Fall in Genesis 3 was not just a moment of weakness but the beginning of all brokenness, driven by humanity's desire to be its own god. Yet even in the middle of that story, God is already moving toward redemption through the promised Lamb.

Join our Discord community! Follow this link and get in on the fun: https://discord.gg/tq88ZNcm3E   Direct Download Link   Meet the Cast:   Jeff Richardson as the Loremaster @eljefetacoma on all the socials   Jayme Antrim as Ebenezer Crunch @brandoff.dice.camp   Kristy Ockunnzi-Kmit as Keziah @kmitko3 Read her short stories at: vocal.media/authors/kristy-ockunzzi-kmit   Ash Blair-Borders as Alecto Ashrender @doktormod on Bluesky   AJ Ganaros as Gale Zauber @aj_the_slayer on Instagram   Theme Song: I'm Taking Off (Shield Your Eyes) by Space Knife released July 4, 2019, used under license, all rights reserved.   Get involved! Contact us: By email: shatteredworldspod@gmail.com or Twitter: @swrpgpod   Get your name on the show! Use the hashtag #swearpig when you tweet about us and we'll name a character after you!   Like our Facebook page - Shattered Worlds RPG   Join our Patreon and help us make more amazing content! Patreon.com/ShatteredWorldsRPG  

Spring is in the air and open water fishing season is almost here. In this episode, Andrew and Jesse talk about the fish they're most excited to target as the ice melts and water temperatures start to rise. From aggressive early season northern pike to the underrated power of freshwater carp, they share what's on their radar for spring fishing in Ontario. They also recap their latest ice fishing trip with Smooth River Guiding and how the day played out on the ice.Kyle Carruthers, organizer of the Cancast Fishing Show joins the podcast to preview Canada's largest fishing show, now merged with Muskie Odyssey for 2026. He shares what anglers can expect in Peterborough on March 29, including vendors, seminars, giveaways, and plenty of fishing gear.Wes from WamBaits also stops by to talk about his newest soft plastic baits he'll be launching at Cancast. To finish the episode, Andrew talks about getting a fishing boat ready for spring, covering maintenance, electronics checks, and tackle prep so anglers are ready when the spring bite turns on.Mentioned in episode: 

Just south of Auckland, a massive development is underway that could become home to 60,000 people. Kiwi Property CEO Clive Mackenzie explains the vision behind Drury — a 50-hectare mixed-use town centre designed to support Auckland’s southward growth. From securing anchor tenants like Costco and New World, to working with government on transport, infrastructure and community facilities, we unpack what it actually takes to build a town from the ground up. This bite is from our episode ‘Kiwi Property’s retail “fortress”’. For more or to watch on YouTube—check out http://linktr.ee/sharedlunchShared Lunch is brought to you by Sharesies Australia Limited (ABN 94 648 811 830; AFSL 529893) in Australia and Sharesies Limited (NZ) in New Zealand. It is not financial advice. Information provided is general only and current at the time it’s provided, and does not take into account your objectives, financial situation and needs. We do not provide recommendations and you should always read the disclosure documents available from the product issuer before making a financial decision. Our disclosure documents and terms and conditions—including a Target Market Determination and IDPS Guide for Sharesies Australian customers—can be found on our relevant Australian or NZ website. Investing involves risk. You might lose the money you start with. If you require financial advice, you should consider speaking with a qualified financial advisor. Past performance is not a guarantee of future performance. Appearance on Shared Lunch is not an endorsement by Sharesies of the views of the presenters, guests, or the entities they represent. Their views are their own.See omnystudio.com/listener for privacy information.

Join Host Bree Carlile as she reads White Fang by Jack London.Follow along as Bree shares her passion for books, audiobooks, and bringing stories to life in these classic novel audiobooks. Busy schedule? Each episode is just one chapter, or bite of a classic novel, play or short story, which means you can fit in your reading goals while getting ready for work, bed, or on your commute.Follow, rate, and review Bite at a Time Books where we read you your favorite classics, one bite at a time. Available wherever you listen to podcasts.Check out our website, or join our Facebook Group!Get exclusive Behind the Scenes content on our YouTube!We are now part of the Bite at a Time Books Productions network!If you ever wondered what inspired your favorite classic novelist to write their stories, what was happening in their lives or the world at the time, check out Bite at a Time Books Behind the Story wherever you listen to podcasts.Follow us on all the socials: Instagram - Twitter - Facebook - TikTokFollow Bree at: Instagram - Twitter - Facebook

Have we got what it takes to wake up? Sanghagita invites us to follow Siddhartha Gautama's extraordinary quest to its turning point. In him, we meet a seeker who turns down power, prestige and leadership, turning his back on the received wisdom of harsh asceticism, choosing instead something far more radical: to meditate alone in the comfortable shade of a beautiful tree. Here he meets Māra: tempter, accuser, embodiment of fear, desire, and doubt, unleashing everything he has to prevent Siddhartha's awakening. How does he respond to each attack? Could we do as well? Are we ready to take our seat as he did, on the diamond throne of The Eternal Buddhas? This talk was given at Sheffield Buddhist Centre, 2026. *** Help us keep FBA Podcasts free for everyone! Donate now: https://freebuddhistaudio.com/donate Subscribe to our Dharmabytes podcast: Bite-sized clips - Buddhist inspiration three times a week. Apple Podcasts: https://podcasts.apple.com/us/podcast/dharmabytes-from-free-buddhist-audio/id416832097 Spotify: https://open.spotify.com/show/4UHPDj01UH6ptj8FObwBfB

This hour Henry expresses his excitement for Kyler Murray signing with the Minnesota Vikings, he gets into why the SAVE Act ISN'T a Voter ID Bill, plus we have Bite of the Night and Headlines.

Nutrition Nugget! Bite-sized bonus episodes offer tips, tricks and approachable science. This week, Jenn is talking about STUFF, Stand Up For Fitness, and why even the most dedicated gym-goers might be living a sedentary lifestyle without realizing it. Could your daily workout actually be giving you a false sense of security when it comes to how much you truly move throughout the day? Jenn breaks down simple, realistic ways to weave more movement into your routine without breaking a sweat or requiring multiple gym visits a day. But here is the real question: Is five minutes of standing every half hour actually enough to counteract hours of sitting? Tune in to find out what Jenn has to say. Like what you're hearing? Be sure to check out the full-length episodes of new releases every Wednesday. Have an idea for a nutrition nugget? Submit it here: https://asaladwithasideoffries.com/index.php/contact/RESOURCES:Become a Happy Healthy Hub MemberJenn's Free Menu PlanA Salad With a Side of FriesA Salad With A Side Of Fries MerchA Salad With a Side of Fries InstagramNutrition Nugget: Dead Butt SyndromeNutrition Nugget: D.W.D.S.Nutrition Nugget: Temptation BundlingKEYWORDS: Jenn Trepeck, Nutrition Nugget, Salad With A Side Of Fries, Health Tips, Wellness Tips, Sedentary Lifestyle Health Risks, Sedentary Lifestyle, Movement Breaks, Stand Up For Fitness, STUFF Philosophy, Exercise Snacks, Standing Desk, Blood Circulation, Brain Fog, Dead Butt Syndrome, Low Back Pain, Hip Flexor Tightness, Sitting Disease, Physical Activity, Wellness Tips, Weight Loss, Nutrition Nugget, Temptation Bundling, Walking After Meals, Dance Break, Squats At Desk, Stretching Breaks, Work From Home Wellness, Desk Job Health, Active Lifestyle, Fitness Habits, Health Coaching, Sedentary Habits, Movement Reminders, Standing Breaks, Exercise Habits, Healthy Living, Posture Health, Mobility, Family Wellness, Outdoor Activity, Gardening For Health, Phone Call Walking, Kitchen Counter Exercises, Body Positioning, Chronic Disease Prevention, How To Break Up Sitting During The Workday, Exercise Snacks For Sedentary Office Workers

Join Host Bree Carlile as she reads White Fang by Jack London.Follow along as Bree shares her passion for books, audiobooks, and bringing stories to life in these classic novel audiobooks. Busy schedule? Each episode is just one chapter, or bite of a classic novel, play or short story, which means you can fit in your reading goals while getting ready for work, bed, or on your commute.Follow, rate, and review Bite at a Time Books where we read you your favorite classics, one bite at a time. Available wherever you listen to podcasts.Check out our website, or join our Facebook Group!Get exclusive Behind the Scenes content on our YouTube!We are now part of the Bite at a Time Books Productions network!If you ever wondered what inspired your favorite classic novelist to write their stories, what was happening in their lives or the world at the time, check out Bite at a Time Books Behind the Story wherever you listen to podcasts.Follow us on all the socials: Instagram - Twitter - Facebook - TikTokFollow Bree at: Instagram - Twitter - Facebook

Welcome to Four Records! Each episode, we feature one guest as they go over four records at four different times in their life. This week, Forrest and Karina speak with Tahlena Chikami, vocalist and guitarist of Bite Me Bambi. Bite Me Bambi has some sh...

Chaz and AJ were out late last night for Loud Island's Bite Bash, and Chaz wiped out while holding two expensive drinks. (0:00) In Dumb Ass News, a Detroit woman called police when a hairdresser pulled a gun on her for $10. (11:30) It is Friday the 13th, and AJ talked about the common superstitions people obey. (19:18) Chaz and AJ asked the Tribe to call in with the commercials that randomly get stuck in their head from when they were growing up. Anyone else remember Mount Airy Lodge? (23:37)St. Patrick's Day parades continue this weekend in Connecticut, including the Milford parade happening tomorrow. Chaz and AJ spoke with Mike McCabe, the chief organizer this morning about how this event has grown rapidly. (36:25) 

What if everything we've been taught about illness only tells half the story? In this episode, Darin dives into one of the most controversial debates in the history of modern medicine: germ theory versus terrain theory. While conventional medicine focuses on identifying pathogens and eliminating them, terrain theory asks a deeper question, why do some people get sick while others exposed to the same pathogen remain perfectly healthy? Tracing the history from Louis Pasteur and Antoine Béchamp to the economic forces that shaped the modern medical system, Darin explores how our internal biological environment, our terrain, may be the real determining factor in health and disease. From cellular voltage and mitochondrial function to microbiome diversity, inflammation, nutrition, toxins, and stress physiology, the science increasingly points toward one central truth: health is shaped by the environment inside the body. Most importantly, Darin breaks down the practical pillars of terrain optimization, simple but powerful daily choices that strengthen resilience, support immunity, and restore the body's natural balance. What You'll Learn The historical battle between germ theory and terrain theory Why exposure to pathogens does not automatically lead to disease The role of Louis Pasteur, Antoine Béchamp, and Claude Bernard in shaping modern medicine How the Flexner Report of 1910 reshaped medical education and marginalized holistic medicine Why modern healthcare often focuses on pathogens instead of the body's internal environment The importance of cellular voltage and mitochondrial health in disease prevention How the microbiome influences immunity, metabolism, and inflammation The surprising connection between vitamin D levels and immune resilience Why chronic inflammation is a central driver of modern diseases How stress, toxins, sleep, and nutrition shape the body's terrain The science behind grounding, sunlight, and circadian rhythm regulation Practical strategies for optimizing your internal terrain and strengthening resilience Chapters 00:00:00 – Welcome to the SuperLife podcast and the mission of building health sovereignty 00:00:33 – Sponsor: reducing plastic waste with Bite toothpaste tablets 00:02:47 – Introduction to today's topic: germ theory vs terrain theory 00:03:10 – Why Darin began exploring this controversial health debate years ago 00:03:54 – What if everything we've been taught about illness is only half the story? 00:04:35 – How our internal biological environment shapes disease susceptibility 00:05:10 – The importance of optimizing the body's internal terrain 00:06:00 – Looking back to the 1800s: the scientific battle that shaped modern medicine 00:06:17 – Louis Pasteur and the rise of germ theory 00:07:20 – The successes of germ theory: antibiotics, vaccines, and sterilization 00:08:01 – Antoine Béchamp and the foundation of terrain theory 00:08:45 – The concept of microbial polymorphism and environmental adaptation 00:09:40 – When microbes become pathogenic in weakened terrain 00:10:00 – Pasteur's alleged deathbed admission: "The microbe is nothing, the terrain is everything" 00:10:45 – Claude Bernard and the concept of the internal environment 00:11:00 – The Flexner Report and the restructuring of American medical education 00:11:45 – How holistic and integrative medical schools were shut down 00:12:30 – The rise of the pharmaceutical-centered medical model 00:13:00 – Why modern doctors often receive little training in nutrition 00:13:45 – The consequences of a pathogen-centered healthcare system 00:14:00 – How economic interests influenced the trajectory of medicine 00:14:20 – Sponsor: Manna Vitality mineral support and cellular optimization 00:16:11 – The science of terrain and how it shows up across multiple disciplines 00:16:47 – Bioelectricity and the role of cellular voltage in health 00:17:20 – The transmembrane potential and healthy cellular voltage levels 00:17:50 – Otto Warburg's discovery of low oxygen environments in cancer cells 00:18:30 – Dr. Jerry Tennant's research on voltage and chronic disease 00:19:00 – The microbiome revolution in modern science 00:19:30 – Why the body contains roughly 38 trillion microbial cells 00:20:00 – How gut bacteria influence immune response 00:20:30 – Research showing microbiome diversity affects viral susceptibility 00:21:00 – Why exposure to pathogens does not always result in illness 00:21:30 – The role of nutrition, sleep, and stress in immune resilience 00:21:55 – Vitamin D deficiency as a major predictor of disease severity 00:22:30 – Chronic inflammation as the root of modern disease 00:23:00 – Mitochondria: the cellular energy system 00:23:40 – How mitochondrial dysfunction contributes to chronic illness 00:24:00 – The connection between nutrient availability and mitochondrial health 00:24:30 – The pillars of terrain optimization 00:25:00 – Why minerals are foundational for cellular health 00:25:30 – Magnesium deficiency and inflammatory disease 00:26:00 – Building a mineral-rich diet for optimal physiology 00:26:20 – Invitation to the SuperLife Patreon community 00:27:55 – Supporting the microbiome through diet and lifestyle 00:28:20 – Why dietary diversity increases microbial resilience 00:29:00 – The importance of sunlight, grounding, and circadian rhythm 00:30:00 – Sleep and the brain's detoxification system 00:31:00 – Environmental toxins and the body's detox pathways 00:31:45 – Stress physiology and its destructive impact on the terrain 00:33:00 – Rebuilding resilience through lifestyle choices 00:34:00 – Final thoughts on reclaiming control over your health 00:35:17 – Closing message and end of episode Thank You to Our Sponsors Bite Toothpaste: Go to trybite.com/DARIN20 or use code DARIN20 for 20% off your first order. Manna Vitality: Go to mannavitality.com/ and use code DARIN12 for 12% off your order.   Join the SuperLife Patreon: This is where Darin now shares the deeper work: - weekly voice notes - ingredient trackers - wellness challenges - extended conversations - community accountability - sovereignty practices Join now for only $7.49/month at https://patreon.com/darinolien Connect with Darin Olien: Website: darinolien.com Instagram: @darinolien Book: Fatal Conveniences Platform & Products: superlife.com New Show: Roadmap to Happiness Key Takeaway: "The germ may be the match, but the terrain is the dry timber. Without the right internal conditions, the spark simply goes out. But when the terrain is depleted—when our bodies are stressed, inflamed, nutrient deficient, and toxic—that same spark can ignite disease. The power we have is in shaping the terrain every single day." Bibliography/Sources: Bai, Y., Ocampo, J., Jin, G., Chen, S., Benet-Martínez, V., Monroy, M., Anderson, C., & Keltner, D. (2021). Awe, daily stress, and well-being. Emotion, 21(4), 562–566. This research documents how individuals experiencing awe report lower levels of daily stress, putting stressors into perspective to increase overall life satisfaction. https://doi.org/10.1037/emo0000638 Becker, R. O., & Selden, G. (1985). The Body Electric: Electromagnetism and the Foundation of Life. A pioneering work documenting how bioelectric fields in the body regulate growth, healing, and immune function. https://www.amazon.com/Body-Electric-Electromagnetism-Foundation-Life/dp/0688069711 Chirico, A., & Yaden, D. B. (2018). Awe: A self-transcendent and sometimes transformative emotion. This chapter identifies awe as a complex emotion arising from vastness that facilitates connectedness and self-diminishment. https://doi.org/10.1007/978-3-319-77619-4_11 DiNicolantonio, J. J., O'Keefe, J. H., & Wilson, W. (2018). Subclinical magnesium deficiency: a principal driver of cardiovascular disease and a public health crisis. Published in Open Heart, this study highlights how magnesium deficiency is a silent driver of inflammatory disease states. https://openheart.bmj.com/content/5/1/e000668 Keltner, D., & Haidt, J. (2003). Approaching awe, a moral, spiritual, and aesthetic emotion. Cognition and Emotion, 17(2), 297–314. A seminal paper establishing the two central pillars of awe: perceived vastness and the need for mental accommodation. https://doi.org/10.1080/02699930302297 Sender, R., Fuchs, S., & Milo, R. (2016). Revised estimates for the number of human and bacteria cells in the body. Published in Cell, this study provides the current understanding that human and microbial cells exist in roughly equal numbers. https://doi.org/10.1016/j.cell.2016.01.013 Warburg, O. (1956). On the origin of cancer cells. Nobel Prize-winning research published in Science establishing that cancer thrives in low-oxygen, low-voltage environments where cellular respiration is impaired. https://doi.org/10.1126/science.123.3191.309

Sometimes midnight is a time of day, and sometimes it's an event, a trial, or a hardship. Today, Amy encourages us in the praise that should pour forth every midnight. References: Psalm 119:62; Psalm 119:171; Revelation 14:7; Philippians 4:4-7 Contact us: devotedpodcast@atheycreek.com women@atheycreek.com https://atheycreek.com/ministries/women Follow us on IG: @atheywomen @ammcreynolds

In this week's Northwest Florida Fishing Report, host Joe Baya covers a classic March transition with updates from the surf, inshore, offshore, and the boating scene. This episode features Justin Reed on the Pensacola to Navarre surf bite, Jim Cox on The Wharf Boat and Yacht Show in Orange Beach, Capt. Blake Nelson on Destin trout and redfish, and Capt. Tyler Massey on Pensacola offshore action. The common thread is that things are improving, but most fisheries are still just on the edge of their full spring pattern. Joe starts with Justin Reed of Justin Reed Fishing for a surf report focused on pompano. Justin says there were a few better days leading up to the full moon, but the bite has been inconsistent since, with redfish, whiting, and catfish filling in while anglers wait for the real run to kick off. He explains why late March into early April still looks like the better window and shares how he staggers baits across the beach to find where fish are traveling. Next, Joe checks in with Jim Cox for a preview of The Wharf Boat and Yacht Show, set for March 20 through 22 at The Wharf in Orange Beach. Jim breaks down what makes the show special, from in-water boats and yachts to hundreds more on land, along with why boat show season can be a great time to compare models and find real buying incentives. From there, Joe talks with Capt. Blake Nelson of Last Cast Charters in Destin about an inshore bite centered on trout and redfish. Blake explains how fish are using creek mouths, bayous, and nearby flats based on food and conditions, and he shares why popping corks with live shrimp and weedless soft plastics are good tools right now. To wrap, Capt. Tyler Massey of Hot Spots Fishing Charters gives an offshore report centered on vermilion snapper and triggerfish. Tyler explains how to find better triggerfish on smaller structure, how he distinguishes vermilions and triggers on the machine, and why April should bring more Spanish mackerel, king mackerel, and other spring opportunities. Sponsors: The Wharf Boat And Yacht Show Dixie Supply and Baker Metal Killerdock Coastal Connection EXP Realty AFTCO SlipSki Solutions Black Buffalo Hilton's Realtime Navigator

Join Host Bree Carlile as she reads White Fang by Jack London.Follow along as Bree shares her passion for books, audiobooks, and bringing stories to life in these classic novel audiobooks. Busy schedule? Each episode is just one chapter, or bite of a classic novel, play or short story, which means you can fit in your reading goals while getting ready for work, bed, or on your commute.Follow, rate, and review Bite at a Time Books where we read you your favorite classics, one bite at a time. Available wherever you listen to podcasts.Check out our website, or join our Facebook Group!Get exclusive Behind the Scenes content on our YouTube!We are now part of the Bite at a Time Books Productions network!If you ever wondered what inspired your favorite classic novelist to write their stories, what was happening in their lives or the world at the time, check out Bite at a Time Books Behind the Story wherever you listen to podcasts.Follow us on all the socials: Instagram - Twitter - Facebook - TikTokFollow Bree at: Instagram - Twitter - Facebook

Send a textAn Eco Bite is a "mini” episode of Eco Speaks CLE. In this shorter format, we reconnect with a past guest or showcase someone new, all in under 15 minutes. In this quick episode, we catch up with Rust Belt Riders and founder Michael Robinson to find out what's new with our favorite worker-owned food waste composting company in Cleveland, Ohio.We first interviewed Rust Belt Riders back in 2022. It was our 4th episode, and we had Dan Brown and Zoe Apisdorf on the show. Since then, Rust Belt Riders has developed new city-supported drop-offs, new commercial infrastructure, and expanded its production of soil and Tilth Soil brand. This cooperative model could scale community composting nationwide through alliances with members of the Community Composting  Coalition. We hope you will enjoy this episode and be part of the story by purchasing Tilth Soil at local retailers and signing up for one of Rust Belt Riders' residential or commercial composting services. Support the showBecome a Subscriber Follow Eco Speaks CLE on LinkedIn, Facebook and InstagramContact - hello@ecospeakscle.com

On this episode the Cincinnati Pink Pony crew joins us at the After Party as they talk about working and partying at the Cincinnati party bar. Matt tells us about his staycations at El Paso County jail and Mad's catches us up from her last episode and her ex drama. Follow us on social media @AaronScenesAfterParty

This hour Henry talks Vikings and NFL with Maybe Matthew Coller from Purple Insider, he chats up Fox 9 News Anchor Randy Meier, plus we have Bite of the Night and Headlines.

Hasbro CEO Chris Cocks just told the anti-Harry Potter activists to kick rocks on a podcast — the company is keeping the Wizarding World toys and games alive no matter how loud the outrage gets. Meanwhile on Bluesky, the usual suspects are already threatening to boycott Magic: The Gathering and Dungeons & Dragons because Hasbro won't cancel J.K. Rowling. Clownfish TV breaks down the latest episode of cancel culture failing spectacularly and why these massive franchises keep surviving the mob.Watch the podcast episodes on YouTube and all major podcast hosts including Spotify.CLOWNFISH TV is an independent, opinionated news and commentary podcast that covers Entertainment and Tech from a consumer's point of view. We talk about Gaming, Comics, Anime, TV, Movies, Animation and more. Hosted by Kneon and Geeky Sparkles.Get more news, views and reviews on Clownfish TV News - https://more.clownfishtv.com/On YouTube - https://www.youtube.com/c/ClownfishTVOn Spotify - https://open.spotify.com/show/4Tu83D1NcCmh7K1zHIedvgOn Apple Podcasts - https://podcasts.apple.com/us/podcast/clownfish-tv-audio-edition/id1726838629

Leslye Headland was going to ruin Yoda forever. The Acolyte showrunner just admitted she planned to make Yoda an active accomplice in covering up Jedi crimes and murders in Season 2. Thankfully Disney cancelled the show before it could happen, but the fact that she even thought this was a good idea shows exactly how broken modern Star Wars has become. Clownfish TV breaks down her shocking comments, why turning the wise Jedi Master into a liar and enabler would have been catastrophic, and what it says about the people currently running the franchise.Watch the podcast episodes on YouTube and all major podcast hosts including Spotify.CLOWNFISH TV is an independent, opinionated news and commentary podcast that covers Entertainment and Tech from a consumer's point of view. We talk about Gaming, Comics, Anime, TV, Movies, Animation and more. Hosted by Kneon and Geeky Sparkles.Get more news, views and reviews on Clownfish TV News - https://more.clownfishtv.com/On YouTube - https://www.youtube.com/c/ClownfishTVOn Spotify - https://open.spotify.com/show/4Tu83D1NcCmh7K1zHIedvgOn Apple Podcasts - https://podcasts.apple.com/us/podcast/clownfish-tv-audio-edition/id1726838629

Jordan Peterson, Elon Musk. The Most Eye Opening 20 Minutes Of Your Life, "Civilization Will Disappear" Unless We Fix This NOW   The Most Eye Opening 20 Minutes Of Your Life | Jordan Peterson Motivation Watch this video at- https://youtu.be/agjhcL9nFQ0?si=ea6I_M6ParaCCSl7 Champions Mentality 365 152K subscribers 1,047,390 views Jan 18, 2026 UNITED STATES The most direct, brutal, and life-changing 20 minutes you'll hear from Jordan Peterson. If you've been feeling stuck, tired of overthinking, tired of wasting time, and tired of staying in the same place while your life slowly slips away... this is for you. Hit play, turn up the volume, and ask yourself one honest question: "Am I becoming stronger... or just staying comfortable?" This video is a carefully curated Jordan Peterson experience designed to wake you up, rebuild your mindset, and force you to confront the truth you've been avoiding. No motivation tricks. No fake hype. Just responsibility, meaning, and real strength built through pain. This video features powerful insights from Jordan Peterson's talks and interviews, centered on: The only way out is through Why weakness destroys your future Becoming dangerous but disciplined How wasted time becomes wasted life Why meaning is a moral obligation How bitterness turns into revenge Turning suffering into strength Who is Jordan Peterson? Jordan Peterson is a Canadian clinical psychologist, former university professor, and bestselling author known worldwide for his teachings on personal responsibility, discipline, meaning, and psychological strength. Over the past decade, he has become one of the most influential voices in modern self-improvement, helping millions of people break out of weakness, confusion, and self-destruction through truth, structure, and personal accountability. He is best known for his books 12 Rules for Life and Beyond Order, where he explains why life is painful, why suffering is unavoidable, and why the only real way forward is to become stronger, more capable, and more disciplined. His message is simple but difficult: stop lying to yourself, stop wasting your time, take responsibility for your life, and build a life that can withstand tragedy. Jordan Peterson's work speaks directly to people who feel lost, unmotivated, anxious, or stuck in comfort and procrastination. He teaches that meaning is not something you find by chasing pleasure - it's something you earn through responsibility, sacrifice, and daily self-improvement. His philosophy has helped people rebuild their mindset, repair their habits, and develop the strength to face life head-on instead of running from it. Follow Jordan Peterson: YouTube:    / @jordanbpeterson   Instagram:   / jordan.b.peterson   Books: 12 Rules for Life: An Antidote to Chaos, Beyond Order: 12 More Rules for Life, and Maps of Meaning: The Architecture of Belief. Special Thanks (Credits): Chris Williamson -    / @chriswillx   Joe Rogan -    / @joerogan   Jocko Willink -    / @jockopodcastofficial   John Stossel -    / @stosseltv   Bite-sized Philosophy -    / @bitesizedphilosophy   Margaret Hoover -    / @firingline   What you'll get in this video: Why being harmless isn't the same as being good How to build real strength and self-control Why wasting time is destroying your future How to stop staying in a miserable situation Why meaning matters more than happiness How responsibility protects you from bitterness How to transform pain into purpose Why watch till the end: This video is designed to push you into action, not just make you feel inspired for 10 minutes. Save it. Rewatch it when you feel lost, weak, or tempted to quit. This is what real mental strength sounds like. Disclaimer & Transformative Use Notice: This video was edited, structured, and produced by Champions Mentality 365 for motivational, educational, and inspirational purposes. All footage, interviews, and speeches have been significantly transformed through original editing, cinematic color grading, narrative restructuring, text commentary, and unique storytelling to create a new, original work. I do not claim ownership of the original clips or audio used. Full credit and respect go to the original speakers, creators, and production teams. This video is created under the principles of Fair Use (Section 107 of the Copyright Act 1976), allowing for transformative uses such as commentary, analysis, motivation, and educational storytelling. No copyright infringement is intended. This project exists to inspire discipline, responsibility, and personal growth. #JordanPeterson #Motivation #Discipline #SelfImprovement #MentalToughness #Mindset #Meaning #Responsibility #NoExcuses #ChampionsMentality365   Elon Musk: "Civilization Will Disappear" Unless We Fix This NOW Watch this video at- https://youtu.be/nfdfaXJxOtw?si=OkhUwhICW_2AQG8O Jesse Kelly 113K subscribers  Mar 10, 2026 Elon Musk is warning about birth rates. How do birth rates link to feminism? Jesse Kelly and Inez Stepman discuss. LIKE & SUBSCRIBE FOR NEW VIDEOS DAILY:    / @jessekellydc   Watch Full Editions Of I'm Right With Jesse Kelly: https://bit.ly/3V2F2Tt Check Out Jesse's Latest Interviews With Big-Name Guests: https://bit.ly/48UxEzn Here Are Jesse's Can't-Miss Monologues: https://bit.ly/3UZBWQl Subscribe To Jesse Kelly Wherever You Get Your Podcasts Apple: https://podcasts.apple.com/us/podcast... Spotify: https://open.spotify.com/show/7fy7hsV... Watch Jesse Kelly nightly on The First TV at 9pm ET: TheFirstTV.com/watch Follow Jesse Kelly On all social platforms X - X.com/@JesseKellyDC Instagram - Instagram.com/JesseKellyShow Facebook - Facebook.com/@JesseKellyDC

Join Host Bree Carlile as she reads White Fang by Jack London.Follow along as Bree shares her passion for books, audiobooks, and bringing stories to life in these classic novel audiobooks. Busy schedule? Each episode is just one chapter, or bite of a classic novel, play or short story, which means you can fit in your reading goals while getting ready for work, bed, or on your commute.Follow, rate, and review Bite at a Time Books where we read you your favorite classics, one bite at a time. Available wherever you listen to podcasts.Check out our website, or join our Facebook Group!Get exclusive Behind the Scenes content on our YouTube!We are now part of the Bite at a Time Books Productions network!If you ever wondered what inspired your favorite classic novelist to write their stories, what was happening in their lives or the world at the time, check out Bite at a Time Books Behind the Story wherever you listen to podcasts.Follow us on all the socials: Instagram - Twitter - Facebook - TikTokFollow Bree at: Instagram - Twitter - Facebook

➡ CLICK HERE to send me a text, I'd love to hear what you thought about this episode! Leave your name in the text so I know who it's from! In today's episode, my friend and neighbor Maura Flaherty, shares the secrets of her longstanding Cookbook Club. For the last 4-5 years, she and 6 other women have been meeting and sharing recipes from a rotating cast of cookbooks and (sometimes) celebrity chefs. And while the recipes have had their moments (see below for some of the faves!), they aren't the true stars of these evenings. That honor belongs to the friends, and to the friendships they've built, nurtured, and deepened across all the courses life has served. (and life has served them some gristle, as you'll hear). I'm so happy to share the tips from Maura about how you might consider creating one of these clubs yourself. And before you turn up your nose because you don't consider yourself a foodie - there's always room at the table for a cocktail or a mocktail! So don't let your skills in the kitchen be a deciding (or limiting!) factor. Support the showI'd love to hear what you think. Drop me a text (linked above) or an email: meagan@meaganschultz.com Or NEW (!) even more fun, drop me a voice memo HERE! Cream City Dreams is now Gather Connect Create! New name, same host

Just Gaymin Podcast S6 Ep 10: A Bite and Slash From the Past Hosted By: Trigger & Honey Recorded On: 03/01/26  In this episode, the hosts dive into: What's the T with JGP: Fun discussion of what is going on in the pod and special topics picked by Trigg and Honey!  Cinema Poo: The hosts discuss "Underworld"

This hour Henry discusses the trend of NBA players always complaining about calls and why that can take away from the enjoyment of the game, he chats up independent political journalist Aaron Rupar from Public Notice Newsletter, plus we have Bite of the Night and Headlines.

Ben Maller talks about people in Baltimore being upset about John Harbaugh signing away Ravens players to the Giants, chatter that the price is going down for WR A.J. Brown from the Eagles, the Raiders and Titans spending the most on Day 1 of 'legal tampering' in free agency, Cite the Bite, and more!See omnystudio.com/listener for privacy information.

Join Host Bree Carlile as she reads White Fang by Jack London.Follow along as Bree shares her passion for books, audiobooks, and bringing stories to life in these classic novel audiobooks. Busy schedule? Each episode is just one chapter, or bite of a classic novel, play or short story, which means you can fit in your reading goals while getting ready for work, bed, or on your commute.Follow, rate, and review Bite at a Time Books where we read you your favorite classics, one bite at a time. Available wherever you listen to podcasts.Check out our website, or join our Facebook Group!Get exclusive Behind the Scenes content on our YouTube!We are now part of the Bite at a Time Books Productions network!If you ever wondered what inspired your favorite classic novelist to write their stories, what was happening in their lives or the world at the time, check out Bite at a Time Books Behind the Story wherever you listen to podcasts.Follow us on all the socials: Instagram - Twitter - Facebook - TikTokFollow Bree at: Instagram - Twitter - Facebook

Join Host Bree Carlile as she reads White Fang by Jack London.Follow along as Bree shares her passion for books, audiobooks, and bringing stories to life in these classic novel audiobooks. Busy schedule? Each episode is just one chapter, or bite of a classic novel, play or short story, which means you can fit in your reading goals while getting ready for work, bed, or on your commute.Follow, rate, and review Bite at a Time Books where we read you your favorite classics, one bite at a time. Available wherever you listen to podcasts.Check out our website, or join our Facebook Group!Get exclusive Behind the Scenes content on our YouTube!We are now part of the Bite at a Time Books Productions network!If you ever wondered what inspired your favorite classic novelist to write their stories, what was happening in their lives or the world at the time, check out Bite at a Time Books Behind the Story wherever you listen to podcasts.Follow us on all the socials: Instagram - Twitter - Facebook - TikTokFollow Bree at: Instagram - Twitter - Facebook